Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 12Neoplasms 10Multiple Myeloma 8Prostatic Neoplasms 6Neoplasm Metastasis 5Giant Cell Tumor of Bone 5Fractures, Bone 4Recurrence 3Osteoporosis 3Bone Neoplasms 3Bone Diseases, Metabolic 3Spinal Cord Compression 2Smoldering Multiple Myeloma 2Parathyroid Neoplasms 2Lymphoma 2Kidney Neoplasms 2Giant Cell Tumors 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Thyroid Neoplasms 1Paraproteinemias 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplastic Processes 1Neoplasms, Plasma Cell 1Multiple Endocrine Neoplasia Type 1 1Melanoma 1Mastocytosis, Systemic 1Lymphoma, Non-Hodgkin 1

Interventions

Phacoemulsification 1Lenalidomide 1Fibroblast Growth Factor 7 1Denosumab 1Cataract Extraction 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Cataract × Denosumab × Clear all
NCT00925600 2017-05-30

Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss

Amgen

Phase 3 Completed
769 enrolled 21 charts
Genitourinary

Bone Diseases, Metabolic, Cataract, Neoplasms, Osteoporosis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡